期刊
ANNALS OF HEMATOLOGY
卷 93, 期 1, 页码 13-32出版社
SPRINGER
DOI: 10.1007/s00277-013-1867-1
关键词
Mycoses; Antifungal agents; Aspergillosis; Invasive candidiasis; Hematologic malignancies
类别
资金
- MSD
- Astellas
- Gilead Sciences
- Pfizer
- Merck Sharp Dohme/Merck
- Basilea
- Gilead
- MSD/Merck
- Deutsche Krebshilfe/German Cancer Aid
- Merck/MSD
- German Federal Ministry of Research and Education (BMBF) [01KN1106]
- Bayer
- Cubist
- F2G
- Genzyme
- GSK
- Miltenyi
- Optimer
- Quintiles
- Sanofi Pasteur
- Viropharma
- Fresenius Biotech
- Bio Rad
- Pierre Fabre Pharma GmbH
- Essex/Schering-Plough
- Janssen
- Schering-Plough
- Essex/MSD
The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient's risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据